340B

The Battle Over 340B

Hospitals and other health care providers say it is an essential tool in ensuring access to care, and to prescription drugs, for their low-income patients. Pharmaceutical companies say it has expanded beyond its original purpose and is being used by hospitals to pad their profits. Members of Congress are divided:  some are supportive and some are skeptical. The section 340B program that requires drug companies to provide discounts to selected hospitals and other providers that serve large numbers of low-income patients has been the subject of controversy in recent years.  During that time, the administration has generally sided with hospitals [...]

2017-11-30T06:00:01-05:00November 30, 2017|Medicare, Medicare regulations|

Long-Awaited 340B Guidance Withdrawn

The long-awaited “guidance” that was expected to bring potentially major changes to the federal section 340B prescription drug discount program has been withdrawn by the Department of Health and Human Services’ Health Resources and Services Administration. The final guidance, based on proposed guidance released in mid-2015, was expected to redefine the patients, providers, and prescription drugs eligible to participate in the 340B program. The document was thought to be in the final stages of review by the Office of Management and Budget. Learn more about the proposed guidance, what it was expected to address, who is relieved and who is [...]

2017-02-06T06:00:56-05:00February 6, 2017|Uncategorized|
Go to Top